Correlations between 6-mercaptopurine treatment-related adverse reactions in children with acute lymphoblastic leukemia and polymorphisms of thiopurine methyltransferase gene
Abstract：Objective To explore 6-mercaptopurine (6-MP) treatment-related adverse reactions in children with acute lymphoblastic leukemia (ALL), and to assess the association between the polymorphisms of thiopurine methyltransferase (TPMT) gene and these 6-MP related toxicities. Methods Total RNA was extracted from bone marrow samples of 46 children with ALL and was then reversed to cDNA. TPMT*1S and *3C were screened by denaturing gradient gel electrophoresis (DGGE) combining with DNA sequencing. Drug toxicities were classified according to national cancer institute-common toxicity criteria version 3.0 (NCI CTC 3.0). The relationship between TPMT gene polymorphisms and the adverse reactions of 6-MP treatment was analyzed. Results During the maintenance treatment period, 22% (10/46) of children discontinued 6-MP treatment because of serious adverse reactions. Two children with TPMT*3C genotypes presented severe adverse reactions, including 1 child with homozygotic mutation who had 6-MP dose-related myelosuppression and hepatotoxicity. The main side effects of 6-MP were myelosuppression, hepatotoxicity and gastrointestinal reaction. And there were no significant differences between TPMT*1S genotypes and severe myelosuppression or hepatotoxicity caused by 6-MP (P>0.05).Conclusions TPMT*3C may correlate with severe adverse reactions caused by 6-MP.
XIE Cai,YUE Li-Jie,DING Hui et al. Correlations between 6-mercaptopurine treatment-related adverse reactions in children with acute lymphoblastic leukemia and polymorphisms of thiopurine methyltransferase gene[J]. CJCP, 2014, 16(5): 499-503.
Hedeland RL, Hvidt K, Nersting J, et al. DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma[J]. Cancer Chemother Pharmacol, 2010, 66(3): 485-491.
Luo XO, Ke ZY, Guan XQ, et al. The comparison of outcome and cost of three protocols for childhood non-high risk acute lymphoblastic leukemiain China[J]. Pediatr Blood Cancer, 2008, 51(2): 204-209.
[5]
Dorababu P, Nagesh N, Linga VG, et al. Epistatic interactions between thiopurine methyltransferase(TPMT) and inosine triphosphate pyrophosphatase (ITPA)[J]. Eur J Clin Pharmacol, 2012, 68(4): 379-387.
[6]
Adam de Beaumais T, Fakhoury M, Medard Y, et al. Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy[J]. Br J Clin Pharmacol, 2011, 71(4): 575-584.
Umamaheswaran G, Krishna Kumar D, Kayathiri D, et al. Inter and intra-ethnic differences in the distribution of the molecular variants of TPMT, UGT1A1 and MDR1 genes in the South Indian population[J]. Mol Biol Rep, 2012, 39(5): 6343-6351.
[9]
Appell ML, Berg J, Duley J, et al. Nomenclature for alleles of the thiopurine methyltransferase gene[J]. Pharmacogenet Genomics, 2013, 23(4): 242-248.
[10]
Hanai H, Iida T, Takeuchi K, et al. Thiopurine maintenance therapy for ulcerative colitis: the clinical significance of monitoring 6-thioguanine nucleotide[J]. Inflamm Bowel Dis, 2010, 16(8): 1376-1381.
[11]
Chisick L, Oleschuk C, Bernstein CN. The utility of thiopurine methyltransferase enzyme testing in inflammatory bowel disease[J]. Can J Gastroenterol, 2013, 27(1): 39-43.
[12]
Takatsu N, Matsui T, Murakami Y, et al. Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease[J]. J Gastroenterol Hepatol, 2009, 24(7): 1258-1264.
